Moderna Inc (MRNA)
125.63
+14.17
(+12.71%)
USD |
NASDAQ |
May 02, 16:00
123.73
-1.90
(-1.51%)
After-Hours: 04:16
Moderna Cash from Investing (TTM): 4.206B for Dec. 31, 2023
Cash from Investing (TTM) Chart
Historical Cash from Investing (TTM) Data
Date | Value |
---|---|
December 31, 2023 | 4.206B |
September 30, 2023 | 3.696B |
June 30, 2023 | 3.852B |
March 31, 2023 | 756.00M |
December 31, 2022 | -5.176B |
September 30, 2022 | -5.266B |
June 30, 2022 | -9.538B |
March 31, 2022 | -12.26B |
December 31, 2021 | -8.523B |
September 30, 2021 | -7.575B |
June 30, 2021 | -5.427B |
Date | Value |
---|---|
March 31, 2021 | -1.536B |
December 31, 2020 | -1.672B |
September 30, 2020 | -1.352B |
June 30, 2020 | -59.34M |
March 31, 2020 | -319.24M |
December 31, 2019 | -15.00M |
September 30, 2019 | -139.12M |
June 30, 2019 | -136.40M |
March 31, 2019 | 98.85M |
December 31, 2018 | -373.09M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (TTM) Range, Past 5 Years
-12.26B
Minimum
Mar 2022
4.206B
Maximum
Dec 2023
-2.447B
Average
-1.352B
Median
Sep 2020
Cash from Investing (TTM) Benchmarks
Eli Lilly and Co | -7.642B |
Merck & Co Inc | -14.08B |
Pfizer Inc | -32.28B |
Johnson & Johnson | -2.901B |
Novavax Inc | -58.81M |